B of A Securities Upgrades Takeda Pharmaceutical to Buy, Announces $20 Price Target
B of A Securities Upgrades Takeda Pharmaceutical to Buy, Announces $20 Price Target
A B 證券升級武田醫藥收購，宣佈 20 美元目標價
B of A Securities analyst Koichi Mamegano upgrades Takeda Pharmaceutical (NYSE:TAK) from Neutral to Buy and announces $20 price target.
B of A Securities分析師Koichi Mamegano將武田製藥(紐約證券交易所代碼：Tak)從中性上調至買入，並宣佈目標價為20美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。